Admission of Equity

29 OCTOBER 2018

BioPharma Credit plc

(the "Company")

Admission of Equity

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, announces that, following the conversion of C Shares into Ordinary Shares in accordance with the announcement made by the Company on 19 October 2018 (RNS: 5338E), 162,118,260 Ordinary Shares of USD 0.01 each will be admitted to trading at 8:00 am today, 29 October 2018.

The Company has made an application for the new Ordinary Shares to be admitted to trading on the Specialist Fund Segment of the Main Market of London Stock Exchange.

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509

Buchanan

+44 (0)20 7466 5000 / [email protected]

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24